HST-1011 drug page Clinical trials

Trials with HST-1011

Every colorectal cancer trial that includes this drug. Those looking for patients come first.

1Trials
0Recruiting
3Countries
77Planned patients

Showing 1–1 of 1

A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
Ongoing, not recruiting Phase 1 77 patients NCT05662397

This is a Phase 1/2 study of HST-1011, a CBL-B inhibitor, being developed for the treatment of patients with advanced solid tumors, who relapsed while on or are refractory to approved anti-PD(L)1 therapies or other standard of care.

United States, Canada, Spain Mar 2023 – Dec 2026 Interventional
Combined with: Cemiplimab